Exome sequencing to predict neoantigens in melanoma

Cancer Immunology Research

Volumn 3, Issue 9, 2015, Pages 992-998

  Pritchard, Antonia L ^a   Burel, Julie G ^a   Neller, Michelle A ^a   Hayward, Nicholas K ^a   Lopez, J Alejandro ^a,b   Fatho, Martina ^c   Lennerz, Volker ^c   Wölfel, Thomas ^c   Schmidt, Christopher W ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; COMPLEMENTARY DNA; DNA METHYLTRANSFERASE 1; EPITOPE; GAMMA INTERFERON; MESSENGER RNA; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLS; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; EXOME SEQUENCING; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MELANOMA; MELANOMA CELL LINE; MEMORY CELL; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN ANALYSIS; TUMOR CELL CULTURE; BIOSYNTHESIS; EXOME; GENETICS; IMMUNOLOGY; MUTATION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; EXOME; HUMANS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MUTATION;

EID: 84962030072     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0088     Document Type: Article

References (19)

1. Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 2011;20:1-17.
2. Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008;20:286-95.
3. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005;102:16013-8.
4. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747-52.
5. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515:572-6.
6. O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387-95.
7. O'Rourke MG, Johnson MK, Lanagan CM, See JL, O'Connor LE, Slater GJ, et al. Dendritic cell immunotherapy for stage IVmelanoma. Melanoma Res 2007;17:316-22.
8. Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 2012;44:165-9.
9. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
10. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
11. Reche PA, Reinherz EL. Prediction of peptide-MHC binding using profiles. Methods Mol Biol 2007;409:185-200.
12. Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003;12:1007-17.
13. Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005;6:132.
14. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009;61:1-13.
15. Rasmussen M, Harndahl M, Stryhn A, Boucherma R, Nielsen LL, Lemonnier FA, et al. Uncovering the peptide-binding specificities of HLA-C: a general strategy to determine the specificity of any MHC class I molecule. J Immunol 2014;193:4790-802.
16. Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol 2013;191:5831-9.
17. Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014;211:2231-48.
18. Feral C, Guellaen G, Pawlak A. Human testis expresses a specific poly (A) - binding protein. Nucleic Acids Res 2001;29:1872-83.
19. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.